Two Major Concerns, page-17

First 17 Last

Share
Profile

Follow
37337

395 Posts.

0

23/04/18

17:14

Post #: 32635345
Share

Originally posted by tommyxu ↑

1. Page 59 of the annual report - The company is in breach of the loan agreement because it did not hit the set EBITDA target. Even under WP, the company did miss its estimation/target.

For the December 2017 quarter, the Group was in breach of an EBITDA covenant in relation to its PFG loan. Consequently, the loan became payable on demand and is disclosed as a Current Financial Liability in the Statement of Financial Position. However, following recent discussions with PFG in February 2018, Admedus has received a waiver of the loan breach and has renegotiated its loan covenants for the 2018 calendar year. If this waiver had been in place by 31 December 2017, $3,500,000 of the loan would have been disclosed as Non-Current Liabilities, reducing the value of Current Liabilities to $8,239,336.

2. Page 11 of the investor presentation

There is no increase for Cardiocel sales from 2016 to 2017 even though there is one more product in the range (Cardiocel Neo). The extra sales was due to new products and that's it. I hope the past is not an indication of the future.

Expand

I think they'll be happy with the warrant they have @ $0.2531 per share. If it passes the resolution.

Resolution 3 – Ratification of Warrant issued to Partners For Growth:

"The PFG Warrant is an unquoted warrant, convertible into 4,938,799 new Shares (Warrant Shares) at an exercise price of $0.2531 per Share and with an expiry date of 25 October 2024."

AHZ Price at posting: 35.0¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

AS2

Capital Compass: Askari Metals advances Ethiopia strategy as permitting remains key focus

NVA

Nova Minerals achieves key milestone on path to Alaskan antimony production

D3E

D3 Energy detects gas in South African helium hunt well

SEN

Senetas experiences stronger cash flow as revenue rises, flags FY27 sales pipeline

HotCopper Highlights Week 35: X2M, AnteoTech and Brighstar dominate forum chatter

CVL

Civmec earnings: Profit climbs as $1.4b order book backs FY27 growth

IMR

Imricor Med and Philips launch commercial iMR lab solution

MEM

Memphasys receives early Thai FDA Felix approval

4DX

4DMedical posts FY26 revenue growth as commercial deployment ramps up

TGN

Tungsten has soared +700% YTD, the US is curbing its exports, and this ASX stock is targeting production in Q1CY27

First 17 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Two Major Concerns, page-17

Top Stories

Capital Compass: Askari Metals advances Ethiopia strategy as permitting remains key focus

Nova Minerals achieves key milestone on path to Alaskan antimony production

D3 Energy detects gas in South African helium hunt well

Senetas experiences stronger cash flow as revenue rises, flags FY27 sales pipeline

HotCopper Highlights Week 35: X2M, AnteoTech and Brighstar dominate forum chatter

Civmec earnings: Profit climbs as $1.4b order book backs FY27 growth

Imricor Med and Philips launch commercial iMR lab solution

Memphasys receives early Thai FDA Felix approval

4DMedical posts FY26 revenue growth as commercial deployment ramps up

Tungsten has soared +700% YTD, the US is curbing its exports, and this ASX stock is targeting production in Q1CY27

Featured News